Inverse Correlation between Natural Killer Cell and Treatment with Enzalutamide
The new androgen-receptor-targeted treatment enzalutamide has been approved for castration-resistant and sensitive prostate cancer with/without metastasis. In this study, Clinical Oncologist Ahmed Zedan investigated natural killer cell activity in patients with metastatic castration-resistant prostate cancer treated with enzalutamide.
Få tilgang
Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.
- Få tilgang
- Hvis du allerede har en profil: Logg in
